| Features: oral antidiabetic agent, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Metformin is a pleiotropic drug: attributed to its action on AMPK Metformin is a biguanide drug used primarily for type 2 diabetes. Mechanistically, it is best described as a bioenergetic modulator: partial inhibition of mitochondrial respiration can raise AMP/ADP, engage AMPK, and suppress mTORC1 signaling; systemically it reduces hepatic gluconeogenesis and can lower insulin/IGF-1 growth signaling. In oncology, observational studies suggested improved outcomes in some settings, but randomized trial data are mixed (e.g., large adjuvant breast cancer data did not show broad benefit overall). Long-term use can be associated with vitamin B12 deficiency, and prescribing requires attention to renal function due to rare lactic acidosis risk in predisposed states. Metformin directly(partially) inhibits Complex I of the electron transport chain (ETC) in mitochondria. This inhibition decreases mitochondrial ATP production and forces cells to rely more on glycolysis for energy. Cancer cells, especially those with high energy demands, may be particularly sensitive to a drop in ATP levels. The inhibition of Complex I also increases the AMP/ATP ratio, setting the stage for the activation of downstream energy stress pathways. AMPK activation results in the inhibition of the mammalian target of rapamycin (mTOR) pathway, a central regulator of protein synthesis and cellular growth. mTOR inhibition reduces cell proliferation and limits tissue growth, which can slow tumor progression. Metformin reduces circulating insulin levels, which in turn can decrease the activation of the insulin and insulin-like growth factor-1 (IGF-1) receptor pathways. ETC Inhibitors: Drugs that directly inhibit specific ETC complexes (e.g., Complex I inhibitors like metformin or phenformin) can increase electron leakage and ROS production.(dose- and context-dependent, and not consistent) -known as mild OXPHOS inhibitor(Complex I modulator)
Time-Scale Flag (TSF): P / R / G
|
| Source: |
| Type: |
| Mitochondrial complex I (NADH:ubiquinone oxidoreductase) is the largest enzyme of the oxidative phosphorylation system. Its function is essential for bioenergetics and redox balance. Altered expression of its subunits can lead to changes in tumor metabolism, reactive oxygen species (ROS) generation, and apoptotic sensitivity—all of which may impact tumor growth and patient outcomes. Commonly Reported Complex I Subunit: -Increased expression of NDUFA4L2 has been associated with poor prognosis -Reduced expression of core complex I subunits (such as NDUFS1 and NDUFS3) may correlate with a poorer overall survival in some cancers -NDUFV1 have been linked to adverse clinical outcomes -Dysregulation of complex I may alter ROS production. In some cancers, controlled ROS production can aid in signaling that promotes cell proliferation or survival, while excessive ROS can trigger cell death. Genes like NDUFA4L2 are also linked with hypoxia, a common feature in the tumor microenvironment. |
| 5800- | MET, | Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:11 Target#:1228 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid